



असर्फी हॉस्पिटल

सबके लिए स्वास्थ्य

AHL/AO/2026/1187

Date: 12.05.2026

To

The BSE Limited

Listing Department

25th Floor, Phiroze Jeejeebhoy Tower

Dalal Street,

Mumbai – 400001

Dear Sir / Ma'am,

Sub: Outcome of Press Release / Media Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code: 543943

With reference to the captioned subject, please find enclosed herewith a **Press Release** titled **“Extract of Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended March 31, 2026”**, issued by the Company today for your information and dissemination.

The aforesaid Press Release has been published in the following newspapers on **12 May 2026** for dissemination to investors and the general public:

- **The Times of India**
- **Dainik Jagran** (Jagran Prakashan Limited)

We request you to kindly take the above information on record and acknowledge the same.

Thanking you,

Yours faithfully,

For **Asarfi Hospital Limited**

Sudipa Singh
CS Sudipa Singh



Company Secretary & Compliance Officer

Membership No.: **ACS 56989**

Encl.: Newspaper Cutting

Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673
Branch Office: Khatal Road, Dhैया, ISM, Dhanbad 826004 || www.asarfihospital.com
Phone: 7808368888, 9234302735 || Email: info@asarfihospital.com




Asarfi Hospital Ltd

CIN: L85110JH2005PLC011673

Regd. Office: 4th Floor, Asarfi Hospital, Baramuri, Bishunpur, Polytechnic, Dhanbad, Jharkhand – 828130, India
Phone: 9608833708 | E-Mail: cs@asarfihospital.com | Website: www.asarfi.in

Leading Dhanbad-based healthcare provider with a 20-year operating track record, running two hospitals across super-specialty and oncology care, delivering integrated healthcare services under one roof, spanning critical care, emergency care, cardiac care, oncology, diagnostics, and other multi-specialty services.



- Strong growth with margin expansion: FY26 revenue rose 42% YoY to ₹173 Cr, with EBITDA margin at 20% and PAT margin at 10%, driven by improved ARPOB, better realizations and enhanced case mix across both hospital units.
- Operational momentum across units: FY26 IPD revenue grew 46% YoY and OPD revenue increased 34% YoY, supported by growth in patient volumes and higher realizations; ARPOB increased to ₹23,020 (Super-Specialty) and ₹37,428 (Cancer Unit).
- Specialty-led performance: Growth was driven by high-acuity specialties including Cardiology, Neurosciences and Orthopaedics in the Super-Specialty unit, along with improved traction in Radiation Oncology at the Cancer unit, strengthening overall revenue mix and complexity of care.

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in Lakhs)

Sl. No	Particulars	STANDALONE				CONSOLIDATED			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		31.03.2026 (Refer Note 3)	31.03.2025 (Refer Note 3)	31.03.2026 (Audited)	31.03.2025 (Audited)	31.03.2026 (Refer Note 3)	31.03.2025 (Refer Note 3)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	4,503.47	3,510.39	17,319.69	12,177.76	4,524.32	3,510.39	17,350.29	12,177.76
2	Other Income	66.54	365.69	278.46	635.71	64.18	360.78	270.17	630.80
3	Total Income	4,570.01	3,876.08	17,598.15	12,813.47	4,588.50	3,871.17	17,620.46	12,808.56
4	Profit before Taxes	507.41	553.51	2,260.95	1,471.45	489.92	529.51	2,219.37	1,431.09
5	Profit after Taxes	409.31	382.86	1,707.66	1,097.96	391.83	358.86	1,666.09	1,057.61
6	Paid-up Equity Share Capital	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73
7	EPS (₹ per share of ₹10/- each)								
	- Basic (In ₹)	2.08	1.95	8.68	5.58	1.99	1.82	8.47	5.37
	- Diluted (In ₹)	2.08	1.95	8.68	5.58	1.99	1.82	8.47	5.37

Notes:

- The Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 11, 2026.
- The above is an extract of the detailed format of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026 filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the websites of Bombay Stock Exchange (www.bseindia.com) and Company's website at www.asarfi.in.
- The figures for the quarter ended March 31, 2026 and March 31, 2025, represent the balancing figures derived between the audited figures for the full financial year and the published year-to-date reviewed figures up to the third quarter of the respective financial years.

For and on behalf of Board of Director
Asarfi Hospital Limited
Sd/-
Udai Pratap Singh
Managing Director
DIN: 08453794

Place: Dhanbad
Date: May 11, 2026




Asarfi Hospital Ltd

CIN: L85110JH2005PLC011673

Regd. Office: 4th Floor, Asarfi Hospital, Baramuri, Bishunpur, Polytechnic, Dhanbad, Jharkhand – 828130, India

Phone: 9608833708 | E-Mail: cs@asarfihospital.com | Website: www.asarfi.in

Leading Dhanbad-based healthcare provider with a 20-year operating track record, running two hospitals across super-specialty and oncology care, delivering integrated healthcare services under one roof, spanning critical care, emergency care, cardiac care, oncology, diagnostics, and other multi-specialty services.



- **Strong growth with margin expansion:** FY26 revenue rose 42% YoY to ₹173 Cr, with EBITDA margin at 20% and PAT margin at 10%, driven by improved ARPOB, better realizations and enhanced case mix across both hospital units.
- **Operational momentum across units:** FY26 IPD revenue grew 46% YoY and OPD revenue increased 34% YoY, supported by growth in patient volumes and higher realizations; ARPOB increased to ₹23,020 (Super-Specialty) and ₹37,428 (Cancer Unit).
- **Specialty-led performance:** Growth was driven by high-acuity specialties including Cardiology, Neurosciences and Orthopaedics in the Super-Specialty unit, along with improved traction in Radiation Oncology at the Cancer unit, strengthening overall revenue mix and complexity of care.

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in Lakhs)

Sl. No	Particulars	STANDALONE				CONSOLIDATED			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025
		(Refer Note 3)	(Refer Note 3)	(Audited)	(Audited)	(Refer Note 3)	(Refer Note 3)	(Audited)	(Audited)
1	Revenue from operations	4,503.47	3,510.39	17,319.69	12,177.76	4,524.32	3,510.39	17,350.29	12,177.76
2	Other Income	66.54	365.69	278.46	635.71	64.18	360.78	270.17	630.80
3	Total Income	4,570.01	3,876.08	17,598.15	12,813.47	4,588.50	3,871.17	17,620.46	12,808.56
4	Profit before Taxes	507.41	553.51	2,260.95	1,471.45	489.92	529.51	2,219.37	1,431.09
5	Profit after Taxes	409.31	382.86	1,707.66	1,097.96	391.83	358.86	1,666.09	1,057.61
6	Paid-up Equity Share Capital	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73	1,967.73
7	EPS (FV per share of Rs 10/- each)								
	- Basic (in Rs)	2.08	1.95	8.68	5.58	1.99	1.82	8.47	5.37
	- Diluted (in Rs)	2.08	1.95	8.68	5.58	1.99	1.82	8.47	5.37

Notes:

- The Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 11, 2026.
- The above is an extract of the detailed format of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026 filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the websites of Bombay Stock Exchange (www.bseindia.com) and Company's website at www.asarfi.in.
- The figures for the quarter ended March 31, 2026 and March 31, 2025, represent the balancing figures derived between the audited figures for the full financial year and the published year-to-date reviewed figures up to the third quarter of the respective financial years.

For and on behalf of Board of Director
Asarfi Hospital Limited
Sd/-
Udai Pratap Singh
Managing Director
DIN: 08453794

Place: Dhanbad
Date: May 11, 2026